Considering the quality of the individual studies, their strengths and weaknesses, it is best shown that mistletoe therapy improves quality of life and tolerability of conventional oncological treatment methods (chemo-, radiotherapy, hormonal therapy, antibody therapy, surgery).
With regard to survival time, a prospective randomised study on advanced pancreatic cancer showed a highly significant prolongation of survival time under mistletoe therapy . Other studies on survival also point in this direction.
It is also documented that the injection of mistletoe extracts can induce tumour remissions. This is consistent with preclinical research on cytotoxicity and its application in animal models .
Reports from doctors with many years of experience in mistletoe therapy indicate that its effectiveness can still be improved by individualizing the therapy regimen. This applies in particular to the specific selection and adjustment of dosage, preparation, host tree, application site and rhythm, and the addition of further interventions .
Currently 157 studies have been conducted on the anthroposophical mistletoe preparations abnobaVISCUM, Helixor, Iscador and Iscucin (status October 2021):
As a result, 152 of 157 studies (= 97 percent) show an advantage for mistletoe therapy. It...
In the selection of studies discussed here, we have limited the studies published since 2004 and those with the highest clinical relevance.
Last update: October 25th, 2021/AT1